PBAC's latest decision on Estradiol: Recommended (2024). Considered for Short-term treatment of climacteric symptoms after natural or surgical menopause. A lower strength formulation (500 microgram) to allow greater flexibility in dosing and reduce product wastage.
PBAC outcome
Recommended
Unrestricted
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
1
first 2024
Submissions
1
2024 → 2024
Eligible population
Women requiring 500 microgram estradiol daily for short-term treatment of climacteric symptoms after natural or surgical menopause.
Therapy area
Endocrinology
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
estradiol 1 mg in 1 gram gel sachet (Sandrena 1 mg)
Economic model
Cost-minimisation
ICER note
Not modelled. This is a minor submission for a new strength of an already-listed drug, presented as a cost-minimisation comparison (substitution from 1 mg to 500 microgram strength).